Puma Biotechnology Inc. (NYSE:PBYI)‘s stock had its “market perform” rating reissued by investment analysts at Cowen and Company in a note issued to investors on Tuesday.

PBYI has been the topic of several other research reports. JPMorgan Chase & Co. set a $89.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Tuesday, September 20th. Stifel Nicolaus restated a “buy” rating and issued a $88.00 target price on shares of Puma Biotechnology in a research note on Thursday, November 10th. Citigroup Inc. set a $88.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research note on Tuesday, September 20th. RBC Capital Markets restated a “sector perform” rating and issued a $46.00 target price (up previously from $36.00) on shares of Puma Biotechnology in a research note on Sunday, July 24th. Finally, Credit Suisse Group AG boosted their target price on shares of Puma Biotechnology from $54.00 to $111.00 and gave the company an “outperform” rating in a research note on Thursday, September 22nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. Puma Biotechnology currently has an average rating of “Buy” and an average target price of $68.56.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology (NYSE:PBYI) opened at 41.80 on Tuesday. The firm’s market capitalization is $1.54 billion. Puma Biotechnology has a one year low of $19.74 and a one year high of $82.81. The firm has a 50 day moving average of $49.34 and a 200 day moving average of $43.92.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Emerald Acquisition Ltd. acquired a new position in shares of Puma Biotechnology during the second quarter valued at about $3,301,000. Quantitative Investment Management LLC acquired a new position in shares of Puma Biotechnology during the second quarter valued at about $425,000. Quantbot Technologies LP acquired a new position in shares of Puma Biotechnology during the second quarter valued at about $183,000. Bank of New York Mellon Corp raised its position in shares of Puma Biotechnology by 5.1% in the second quarter. Bank of New York Mellon Corp now owns 111,918 shares of the biopharmaceutical company’s stock valued at $3,333,000 after buying an additional 5,423 shares during the period. Finally, Northern Capital Management LLC raised its position in shares of Puma Biotechnology by 1.2% in the second quarter. Northern Capital Management LLC now owns 16,288 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 190 shares during the period. 87.54% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

5 Day Chart for NYSE:PBYI

Receive News & Stock Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related stocks with our FREE daily email newsletter.